|
May 16 , 2005
MEDICURE TO PRESENT AT BIOTECH INVESTOR CONFERENCES
WINNIPEG, Manitoba Ð (May 16, 2005)
WINNIPEG , Manitoba – (May 16, 2005) Medicure Inc. (TSX:MPH/Amex:MCU), a cardiovascular drug discovery and development company, is pleased to announce that it will be presenting at two upcoming biotech investor conferences.
On Wednesday, May 18, 2005, Medicure’s Vice President of Market & Business Development, Moray Merchant, will present at BioFinance in Toronto, Ontario. BioFinance is Canada’s largest annual life sciences business gathering. Mr. Merchant is scheduled to present at 2:30 pm EST in the Trinity II Room of the Marriott Eaton Centre.
On Thursday, May 26, 2005, Albert D. Friesen PhD, Medicure’s President and Chief Executive Officer will present at the Needham Biotechnology Conference in New York. The Needham conference provides a forum for leading biotechnology company executives to interact with leaders from the investment community. Dr. Friesen is scheduled to present at 3:00 pm EST at the New York Palace Hotel.
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development Company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine, the largest pharmaceutical market sector. The Company's solid position in this field is supported by the following attributes:
- Cardiovascular focused pipeline: a global market of over US $70 billion
- Two drugs - MC-1 & MC-4232 - in advanced Phase II trials
- Two positive Phase II trials completed
- Unique products addressing major markets not adequately served by existing drugs
- Second combination product, MC-4262 is entering development stage
- Dual action antithrombotic, MC-45308, with positive preclinical results
The Company's financial position remains solid, providing sufficient resources to complete the ongoing Phase II studies, and to advance the lead candidates up to pivotal Phase III studies.
Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule, anti-ischemics and anti-thrombotics towards human clinical studies.
This press release contains forward-looking statements that involve risks, which may cause actual results to differ materially from the statements made, and accordingly may be deemed to be forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Hogan Mullally
Manager of Investor & Public Relations
Medicure Inc.
888-435-2220
204-488-9823 fax
info@medicure.com
Back to News Releases
|
